Detalles de la búsqueda
1.
Obesity and immune-checkpoint inhibitors in advanced melanoma: A meta-analysis of survival outcomes from clinical studies.
Semin Cancer Biol;
91: 27-34, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871633
2.
Synchronous occurrence of primary cutaneous B-cell lymphoma and cutaneous Rosai-Dorfman disease in distinct lesions: A unique association.
J Cutan Pathol;
51(1): 7-10, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36636954
3.
Predictors of Recurrence and Progression in Poorly Differentiated Cutaneous Squamous Cell Carcinomas: Insights from a Real-Life Experience.
Dermatology;
240(2): 329-336, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38008073
4.
Safety of omalizumab in chronic urticaria during pregnancy: a real-life study.
Clin Exp Dermatol;
49(4): 344-347, 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37956096
5.
Sentinel lymph node biopsy versus observation in high-risk cutaneous squamous cell carcinoma in immunosuppressed and immunocompetent patients: An inverse probability of treatment weighting study.
J Eur Acad Dermatol Venereol;
2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38738666
6.
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.
J Eur Acad Dermatol Venereol;
2024 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38284131
7.
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
J Dtsch Dermatol Ges;
22(1): 34-42, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926830
8.
The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
Cancer;
129(15): 2331-2340, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37162404
9.
Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: Data up to 3 years.
Exp Dermatol;
32(6): 852-858, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36856013
10.
The Limitation of Accessing Hospital Services Due to COVID-19 Pandemic: A Pilot Study of the Telephone Triage to Re-Organize the Access to a Center for Sexual Health in Northwest Italy.
Sex Transm Dis;
50(9): 603-606, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36728659
11.
Follicular colonization in melanocytic nevi and melanoma: A literature review.
J Cutan Pathol;
50(8): 773-778, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36820529
12.
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
J Eur Acad Dermatol Venereol;
37(10): 1991-1998, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335879
13.
The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086).
BMC Cancer;
22(1): 610, 2022 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35659273
14.
Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis.
Dermatol Ther;
35(5): e15407, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35218275
15.
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
Dermatol Ther;
35(12): e15866, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36175129
16.
Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
Dermatol Ther;
35(11): e15803, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36062429
17.
Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis.
Dermatol Ther;
35(12): e15917, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36214268
18.
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
Dermatol Ther;
35(10): e15670, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762118
19.
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Dermatol Ther;
35(5): e15378, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35156278
20.
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Dermatol Ther;
35(6): e15492, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35384181